| DIRECT COMPETITOR COMPARISON | |
| PBIO | A | Pvt1 | TMO | Industry | | Market Cap: | 3.60M | 10.20B | N/A | 19.62B | 59.95M | | Employees: | 13 | 17,000 | N/A | 34,500 | 56 | | Qtrly Rev Growth (yoy): | 19.50% | -21.20% | N/A | -2.20% | 18.90% | | Revenue (ttm): | 1.23M | 4.48B | 1.03B1 | 9.92B | 12.73M | | Gross Margin (ttm): | 64.29% | 51.15% | N/A | 39.87% | 50.63% | | EBITDA (ttm): | -3.12M | 209.00M | N/A | 1.88B | -1.76M | | Oper Margins (ttm): | -270.19% | 1.05% | N/A | 11.14% | -19.80% | | Net Income (ttm): | -2.75M | -31.00M | N/A | 878.50M | N/A | | EPS (ttm): | -1.251 | -0.090 | N/A | 2.070 | N/A | | P/E (ttm): | N/A | N/A | N/A | 23.22 | 23.74 | | PEG (5 yr expected): | N/A | 1.64 | N/A | 1.93 | 1.33 | | P/S (ttm): | 2.98 | 2.27 | N/A | 1.97 | 3.00 |
|
| A = Agilent Technologies Inc. | | Pvt1 = BD Biosciences (privately held) | | TMO = Thermo Fisher Scientific, Inc. | | Industry = Diagnostic Substances | | 1 = As of 2007 |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.50 | 0.74% | 58.20B | 12.54 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.74 | -0.21% | 13.81B | 15.98 | | Genzyme Corp. | GENZ | 51.29 | 0.35% | 13.61B | 29.24 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.54 | 0.30% | 41.88B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.04 | 0.55% | 9.10B | 1041.63 | | Teva Pharmaceutical Industries Limited | TEVA | 53.94 | 1.05% | 47.52B | 49.35 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.68 | 0.35% | 4.00B | 19.42 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.77 | -1.01% | 2.92B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.51 | 1.54% | 5.66B | 113.56 | | Pfizer Inc. | PFE | 18.74 | -0.58% | 151.22B | 15.56 | | Johnson & Johnson | JNJ | 63.88 | 0.58% | 176.25B | 13.95 | | GlaxoSmithKline plc | GSK | 42.38 | -0.07% | 107.43B | 13.50 | | Sanofi-Aventis | SNY | 39.75 | 1.09% | 103.79B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.77 | -0.69% | 126.66B | 16.70 | | RHHBY.PK | 41.43 | 0.07% | N/A | N/A | | AstraZeneca plc | AZN | 45.93 | 0.42% | 66.60B | 9.22 | | Abbott Laboratories | ABT | 54.44 | -0.07% | 84.20B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 24.77 | 0.49% | 49.07B | 12.81 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|